<p>诺瓦瓦克斯公司（NASDAQ:NVAX - 获取免费报告）董事 Rachel K. King 于 12 月 13 日星期五出售了 4,150 股该公司的股票。股票以平均价格 9.02 美元出售，总价值为 37,433.00 美元。出售后，该董事现在直接拥有 14,770 股公司的股票，价值为 133,225.40 美元。这代表着他们持有的股票减少了 21.93%。此次出售在向美国证券交易委员会（SEC）提交的文件中披露，相关信息可在 SEC 网站上查阅。</p>
<h2>诺瓦瓦克斯价格表现</h2>
<ul>
<li>生物科技的牛市结束了吗？选举影响的分析</li>
</ul>
<p>在周四的午盘交易中，NASDAQ:NVAX 上涨 0.53 美元，达到 8.57 美元。该公司股票的交易量为 3,813,721 股，而其平均交易量为 9,060,255 股。该公司的 50 日移动平均价格为 8.74 美元，200 日移动平均价格为 11.40 美元。该公司的市值为 13.7 亿美元，市盈率为-3.79，贝塔值为 2.02。诺瓦瓦克斯公司的 12 个月低点为 3.53 美元，12 个月高点为 23.86 美元。</p>
<p>诺瓦瓦克斯（NASDAQ:NVAX - 获取免费报告）最近于 11 月 12 日星期二发布了季度财报。这家生物制药公司报告本季度每股收益为-0.76 美元，超出市场共识预期的-0.83 美元，超出幅度为 0.07 美元。该公司本季度的收入为 8451 万美元，而分析师预期为 6580 万美元。诺瓦瓦克斯本季度的收入同比下降了 54.8%。在去年同期，该公司每股收益为-1.26 美元。整体来看，分析师预测诺瓦瓦克斯公司今年的每股收益将为-1.44 美元。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>Moderna 在第二季度财报后下跌，但能否因空头回补而反弹？</li>
</ul>
<p>一些分析师最近对 NVAX 股票发表了评论。杰富瑞金融集团将诺瓦瓦克斯的目标价从 31.00 美元下调至 25.00 美元，并在 10 月 16 日的研究报告中给予该公司 “买入” 评级。HC Wainwright 在 12 月 10 日的研究报告中重申了 “买入” 评级，并将诺瓦瓦克斯的目标价设定为 19.00 美元。最后，B. Riley 在 10 月 10 日的报告中重新发布了 “买入” 评级，并将诺瓦瓦克斯的目标价从 23.00 美元上调至 26.00 美元。一位股票研究分析师对该股票给予了 “卖出” 评级，两位给予了 “持有” 评级，三位给予了 “买入” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，平均目标价为 17.83 美元。</p>
<p><strong>获取我们对诺瓦瓦克斯的最新股票分析</strong></p>
<h2>对诺瓦瓦克斯的对冲基金观点</h2>
<ul>
<li>诺瓦瓦克斯因财报失利暴跌：是下跌刀还是买入机会？</li>
</ul>
<p>几家对冲基金和其他机构投资者最近调整了对 NVAX 的持股。查尔斯·施瓦布投资管理公司在第三季度将其在诺瓦瓦克斯的持股增加了 16.5%。查尔斯·施瓦布投资管理公司目前拥有 1,325,508 股生物制药公司的股票，价值为 16,741,000 美元，此前在该期间又购买了 187,548 股。蒙特利尔银行在第三季度将其在诺瓦瓦克斯的持股增加了 26.7%。蒙特利尔银行目前拥有 2,454,325 股生物制药公司的股票，价值为 32,643,000 美元，此前在上个季度又购买了 517,727 股。Shah Capital Management 在第二季度将其在诺瓦瓦克斯的持股增加了 19.0%。Shah Capital Management 目前拥有 9,662,090 股生物制药公司的股票，价值为 122,322,000 美元，此前在上个季度又收购了 1,544,263 股。道富银行在第三季度将其在诺瓦瓦克斯的持股增加了 26.7%。道富银行目前拥有 7,687,951 股生物制药公司的股票，价值为 97,099,000 美元，此前在上个季度又购买了 1,621,772 股。最后，Vontobel Holding Ltd.在第三季度将其在诺瓦瓦克斯的持股增加了 110.3%。Vontobel Holding Ltd.目前拥有 498,532 股生物制药公司的股票，价值为 6,296,000 美元，此前在上个季度又收购了 261,464 股。53.04% 的股票由机构投资者持有。</p>
<h2>诺瓦瓦克斯公司简介</h2>
<p>（获取免费报告）</p>
<p>诺瓦瓦克斯公司是一家生物技术公司，通过发现、开发和商业化疫苗来促进健康，以保护人们免受严重传染病的侵害。它提供的疫苗平台结合了重组蛋白方法、纳米颗粒技术和其专利的 Matrix-M 佐剂，以增强免疫反应。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过诺瓦瓦克斯</li>
<li>3 只沃伦·巴菲特在波动时期必须购买的股票</li>
<li>3 家重新崛起的科技公司成为人工智能领导者</li>
<li>FAANG 股票是什么？它们是好的投资吗？</li>
<li>分析师最喜欢的网络安全股票：3 个顶级选择</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>分析师看好：3 家科技巨头的目标价上调</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<p>→ 3 CENT 加密货币将在 12 月 16 日爆炸？（来自真正的市场内部人士）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTE0MA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTE0MA"/></p>
<h2>你现在应该投资 1,000 美元在诺瓦瓦克斯吗？</h2>
<p>在考虑诺瓦瓦克斯之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而诺瓦瓦克斯并不在名单上。</p>
<p>虽然诺瓦瓦克斯目前在分析师中被评为 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

诺瓦瓦克斯医药

<p>Rachel K. King，诺瓦瓦克斯医药（NASDAQ:NVAX）的一名董事，出售了 4,150 股公司股票，平均价格为 9.02 美元，总计 37,433 美元。此次交易后，她的持股比例减少了 21.93%，剩余 14,770 股，价值 133,225.40 美元。该出售在美国证券交易委员会的备案中披露。诺瓦瓦克斯的股票经历了波动，最近的交易价格为 8.57 美元，市值为 13.7 亿美元。分析师对该股票的评级不一，平均目标价格为 17.83 美元</p>

<p>Novavax, Inc. (NASDAQ:NVAX - Get Free Report) Director Rachel K. King sold 4,150 shares of the business's stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $9.02, for a total value of $37,433.00. Following the sale, the director now directly owns 14,770 shares of the company's stock, valued at $133,225.40. This represents a 21.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.</p>
<div class="lb-trans"><p>诺瓦瓦克斯公司（NASDAQ:NVAX - 获取免费报告）董事 Rachel K. King 于 12 月 13 日星期五出售了 4,150 股该公司的股票。股票以平均价格 9.02 美元出售，总价值为 37,433.00 美元。出售后，该董事现在直接拥有 14,770 股公司的股票，价值为 133,225.40 美元。这代表着他们持有的股票减少了 21.93%。此次出售在向美国证券交易委员会（SEC）提交的文件中披露，相关信息可在 SEC 网站上查阅。</p>
</div><h2>Novavax Price Performance</h2>
<div class="lb-trans"><h2>诺瓦瓦克斯价格表现</h2>
</div><ul>
<li>Is Biotech’s Bull Run Over? Examining Election Impacts</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技的牛市结束了吗？选举影响的分析</li>
</ul>
</div><p>NASDAQ:NVAX traded up $0.53 during mid-day trading on Thursday, reaching $8.57. 3,813,721 shares of the company's stock traded hands, compared to its average volume of 9,060,255. The company has a 50 day moving average price of $8.74 and a 200-day moving average price of $11.40. The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of -3.79 and a beta of 2.02. Novavax, Inc. has a 12-month low of $3.53 and a 12-month high of $23.86.</p>
<div class="lb-trans"><p>在周四的午盘交易中，NASDAQ:NVAX 上涨 0.53 美元，达到 8.57 美元。该公司股票的交易量为 3,813,721 股，而其平均交易量为 9,060,255 股。该公司的 50 日移动平均价格为 8.74 美元，200 日移动平均价格为 11.40 美元。该公司的市值为 13.7 亿美元，市盈率为-3.79，贝塔值为 2.02。诺瓦瓦克斯公司的 12 个月低点为 3.53 美元，12 个月高点为 23.86 美元。</p>
</div><p>Novavax (NASDAQ:NVAX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.07. The firm had revenue of $84.51 million during the quarter, compared to analysts' expectations of $65.80 million. Novavax's revenue for the quarter was down 54.8% on a year-over-year basis. During the same period in the previous year, the company earned ($1.26) earnings per share. As a group, analysts forecast that Novavax, Inc. will post -1.44 EPS for the current year.</p>
<div class="lb-trans"><p>诺瓦瓦克斯（NASDAQ:NVAX - 获取免费报告）最近于 11 月 12 日星期二发布了季度财报。这家生物制药公司报告本季度每股收益为-0.76 美元，超出市场共识预期的-0.83 美元，超出幅度为 0.07 美元。该公司本季度的收入为 8451 万美元，而分析师预期为 6580 万美元。诺瓦瓦克斯本季度的收入同比下降了 54.8%。在去年同期，该公司每股收益为-1.26 美元。整体来看，分析师预测诺瓦瓦克斯公司今年的每股收益将为-1.44 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?</li>
</ul>
<div class="lb-trans"><ul>
<li>Moderna 在第二季度财报后下跌，但能否因空头回补而反弹？</li>
</ul>
</div><p>A number of analysts recently commented on NVAX shares. Jefferies Financial Group decreased their price target on Novavax from $31.00 to $25.00 and set a &#34;buy&#34; rating for the company in a research report on Wednesday, October 16th. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $19.00 target price on shares of Novavax in a research report on Tuesday, December 10th. Finally, B. Riley reissued a &#34;buy&#34; rating and issued a $26.00 price target (up from $23.00) on shares of Novavax in a report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and an average price target of $17.83.</p>
<div class="lb-trans"><p>一些分析师最近对 NVAX 股票发表了评论。杰富瑞金融集团将诺瓦瓦克斯的目标价从 31.00 美元下调至 25.00 美元，并在 10 月 16 日的研究报告中给予该公司 “买入” 评级。HC Wainwright 在 12 月 10 日的研究报告中重申了 “买入” 评级，并将诺瓦瓦克斯的目标价设定为 19.00 美元。最后，B. Riley 在 10 月 10 日的报告中重新发布了 “买入” 评级，并将诺瓦瓦克斯的目标价从 23.00 美元上调至 26.00 美元。一位股票研究分析师对该股票给予了 “卖出” 评级，两位给予了 “持有” 评级，三位给予了 “买入” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，平均目标价为 17.83 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Novavax</strong></p>
<div class="lb-trans"><p><strong>获取我们对诺瓦瓦克斯的最新股票分析</strong></p>
</div><h2>Hedge Funds Weigh In On Novavax</h2>
<div class="lb-trans"><h2>对诺瓦瓦克斯的对冲基金观点</h2>
</div><ul>
<li>Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?</li>
</ul>
<div class="lb-trans"><ul>
<li>诺瓦瓦克斯因财报失利暴跌：是下跌刀还是买入机会？</li>
</ul>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of NVAX. Charles Schwab Investment Management Inc. grew its holdings in Novavax by 16.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,325,508 shares of the biopharmaceutical company's stock valued at $16,741,000 after purchasing an additional 187,548 shares during the period. Bank of Montreal Can grew its position in shares of Novavax by 26.7% during the third quarter. Bank of Montreal Can now owns 2,454,325 shares of the biopharmaceutical company's stock valued at $32,643,000 after purchasing an additional 517,727 shares in the last quarter. Shah Capital Management increased its stake in Novavax by 19.0% in the 2nd quarter. Shah Capital Management now owns 9,662,090 shares of the biopharmaceutical company's stock worth $122,322,000 after acquiring an additional 1,544,263 shares during the last quarter. State Street Corp raised its stake in Novavax by 26.7% during the third quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company's stock valued at $97,099,000 after purchasing an additional 1,621,772 shares in the last quarter. Finally, Vontobel Holding Ltd. lifted its holdings in shares of Novavax by 110.3% in the 3rd quarter. Vontobel Holding Ltd. now owns 498,532 shares of the biopharmaceutical company's stock valued at $6,296,000 after acquiring an additional 261,464 shares during the last quarter. 53.04% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近调整了对 NVAX 的持股。查尔斯·施瓦布投资管理公司在第三季度将其在诺瓦瓦克斯的持股增加了 16.5%。查尔斯·施瓦布投资管理公司目前拥有 1,325,508 股生物制药公司的股票，价值为 16,741,000 美元，此前在该期间又购买了 187,548 股。蒙特利尔银行在第三季度将其在诺瓦瓦克斯的持股增加了 26.7%。蒙特利尔银行目前拥有 2,454,325 股生物制药公司的股票，价值为 32,643,000 美元，此前在上个季度又购买了 517,727 股。Shah Capital Management 在第二季度将其在诺瓦瓦克斯的持股增加了 19.0%。Shah Capital Management 目前拥有 9,662,090 股生物制药公司的股票，价值为 122,322,000 美元，此前在上个季度又收购了 1,544,263 股。道富银行在第三季度将其在诺瓦瓦克斯的持股增加了 26.7%。道富银行目前拥有 7,687,951 股生物制药公司的股票，价值为 97,099,000 美元，此前在上个季度又购买了 1,621,772 股。最后，Vontobel Holding Ltd.在第三季度将其在诺瓦瓦克斯的持股增加了 110.3%。Vontobel Holding Ltd.目前拥有 498,532 股生物制药公司的股票，价值为 6,296,000 美元，此前在上个季度又收购了 261,464 股。53.04% 的股票由机构投资者持有。</p>
</div><h2>Novavax Company Profile</h2>
<div class="lb-trans"><h2>诺瓦瓦克斯公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.</p>
<div class="lb-trans"><p>诺瓦瓦克斯公司是一家生物技术公司，通过发现、开发和商业化疫苗来促进健康，以保护人们免受严重传染病的侵害。它提供的疫苗平台结合了重组蛋白方法、纳米颗粒技术和其专利的 Matrix-M 佐剂，以增强免疫反应。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Novavax</li>
<li>3 Must-Buy Warren Buffett Stocks for Volatile Times</li>
<li>3 Legacy Tech Companies Reemerging as AI Leaders</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks</li>
<li>What is a Secondary Public Offering? What Investors Need to Know</li>
<li>Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过诺瓦瓦克斯</li>
<li>3 只沃伦·巴菲特在波动时期必须购买的股票</li>
<li>3 家重新崛起的科技公司成为人工智能领导者</li>
<li>FAANG 股票是什么？它们是好的投资吗？</li>
<li>分析师最喜欢的网络安全股票：3 个顶级选择</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>分析师看好：3 家科技巨头的目标价上调</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><p>→ 3 CENT Crypto to Explode December 16th? (From True Market Insiders)(Ad)</p>
<div class="lb-trans"><p>→ 3 CENT 加密货币将在 12 月 16 日爆炸？（来自真正的市场内部人士）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTE0MA" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=11140&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Novavax right now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在诺瓦瓦克斯吗？</h2>
</div><p>Before you consider Novavax, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑诺瓦瓦克斯之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而诺瓦瓦克斯并不在名单上。</p>
</div><p>While Novavax currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然诺瓦瓦克斯目前在分析师中被评为 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Rachel K. King 出售了 4,150 股诺瓦瓦克斯医药公司（NASDAQ:NVAX）的股票